Aclaris reports potential of ATI-2138 as a dual inhibitor for inflammatory diseases, with promising preclinical and clinical trial results. Aclaris Therapeutics, Inc. has announced the publication of ...
- Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) - WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Aclaris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback